The KRAS Mutational Spectrum and Its Clinical Implications in Pancreatic Cancer

Authors

Luigi Perelli
Giannicola Genovese
Giulio F Draetta

Language

English

Publication Date

9-9-2024

Journal

Cancer Cell

DOI

10.1016/j.ccell.2024.08.001

PMID

39214093

Abstract

In this issue of Cancer Cell, McIntyre et al. show that specific mutations in the KRAS proto-oncogene shape clinical progression of pancreatic ductal adenocarcinoma (PDAC). Importantly, they find that the KRASG12R mutation is enriched in early-stage PDAC, and it is characterized by distinctly activated molecular programs.

Keywords

Humans, Proto-Oncogene Mas, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation, Carcinoma, Pancreatic Ductal

Published Open-Access

yes

Recommended Citation

Luigi Perelli, Giannicola Genovese, and Giulio F Draetta, "The KRAS Mutational Spectrum and Its Clinical Implications in Pancreatic Cancer" (2024). Faculty, Staff and Student Publications. 5602.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5602